Professor | Bo Zhu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Bo Zhu
Contact Information	bo.zhu@tmmu.edu.cn
Language ability	English, Chinese
Province	Chongqing

Upload Avatar (500 x 500)

Name

Bo Zhu

Contact Information

bo.zhu@tmmu.edu.cn

Language ability

English, Chinese

Province

Chongqing

University/Lab Affiliation and Title	Chongqing Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	1992.09-1997.07 Bachelor in Clinical Medicine: Third Military Medical University 1997.09-2000.07 Master in Experimental Hematology: Third Military Medical University 2000.09-2003.07 PhD in Oncology: Third Military Medical University Published over 100 papers in international journals, with 25 papers having an impact factor greater than 10 Authored/Co-authored 3 monographs and 11 clinical guidelines Received National Natural Science Second Prize, Chongqing Natural Science First Prize, Chongqing Science Progress Second Prize, Chinese Medical Science and Technology Progress First Prize, and Ministry of Education Natural Science Second Prize
Work Experience	2003.07-2005.07 Attending Physician, Lecturer: Second Affiliated Hospital of Third Military Medical University 2005.07-2007.12 Postdoctoral Researcher: Queen Mary University of London 2005.07-2008.12 Associate Professor, Associate Chief Physician: Second Affiliated Hospital of Third Military Medical University 2008.12-2012.06 Deputy Director, Professor, Doctoral Supervisor: Second Affiliated Hospital of Third Military Medical University 2012.06-present Director, Professor, Doctoral Supervisor: Second Affiliated Hospital of Army Medical University
Awards	National Natural Science Second Prize Chongqing Natural Science First Prize Chongqing Science Progress Second Prize Chinese Medical Science and Technology Progress First Prize Ministry of Education Natural Science Second Prize

University/Lab Affiliation and Title

Chongqing Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

1992.09-1997.07 Bachelor in Clinical Medicine: Third Military Medical University
1997.09-2000.07 Master in Experimental Hematology: Third Military Medical University
2000.09-2003.07 PhD in Oncology: Third Military Medical University
Published over 100 papers in international journals, with 25 papers having an impact factor greater than 10
Authored/Co-authored 3 monographs and 11 clinical guidelines
Received National Natural Science Second Prize, Chongqing Natural Science First Prize, Chongqing Science Progress Second Prize, Chinese Medical Science and Technology Progress First Prize, and Ministry of Education Natural Science Second Prize

Work Experience

2003.07-2005.07 Attending Physician, Lecturer: Second Affiliated Hospital of Third Military Medical University
2005.07-2007.12 Postdoctoral Researcher: Queen Mary University of London
2005.07-2008.12 Associate Professor, Associate Chief Physician: Second Affiliated Hospital of Third Military Medical University
2008.12-2012.06 Deputy Director, Professor, Doctoral Supervisor: Second Affiliated Hospital of Third Military Medical University
2012.06-present Director, Professor, Doctoral Supervisor: Second Affiliated Hospital of Army Medical University

Awards

National Natural Science Second Prize
Chongqing Natural Science First Prize
Chongqing Science Progress Second Prize
Chinese Medical Science and Technology Progress First Prize
Ministry of Education Natural Science Second Prize

Areas of Focus	Tumor Immunology
Publications	Tumor-associated myeloid cells in cancer immunotherapy, Cheng X, Wang H, Wang Z, Zhu B, Long H, 2023 CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy, Xinxin Wang#, Haoran Zha#, Wei Wu, Ting Yuan, Shuanglong Xie, Zheng Jin, Haixia Long, Fei Yang, Zhongyu Wang, Anmei Zhang, Jianbao Gao, Ying Jiang, Lujing Wang, Chunyan Hu, Yisong Y. Wan, Qi-Jing Li, Alistair L.J. Symonds, Qingzhu Jia, Bo Zhu, 2023 Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy, Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B, 2022 High-throughput single-сell sequencing in cancer research, Jia Q, Chu H, Jin Z, Long H, Zhu B, 2022 Modulating tumor physical microenvironment for fueling CAR-T cell therapy, Luo Z, Yao X, Li M, Fang D, Fei Y, Cheng Z, Xu Y, Zhu B, 2022 Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing During Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer, Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, Wu D, Li X, Sun J, He L, Robinson B, Zhu B, 2020 Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC, Wang Z, Jia Q, Tang X, Yan L, Zhu B, 2020 The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection, Chen X#, Cao G#, Wu J#, Wang X#, Pan Z, Gao J, Tian Q, Xu L, Li Z, Hao Y, Huang Q, Wang P, Xiao M, Xie L, Tang S, Liu Z, Hu L, Tang J, He R, Wang L, Zhou X, Wu Y, Chen M, Sun B, Zhu B, Huang J, Ye L, 2020 Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients with Lung Adenocarcinoma, Gong Z#; Jia Q#; Chen J; Diao X; Gao J; Wang X; Zhu B, 2019 Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation, Zhou J#, Huang S#, Wang Z#, Huang J, Xu L, Tang X, Wan YY, Li QJ, Symonds ALJ, Long H, Zhu B, 2019 Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells, Zhao L#; He R#; Long H#; Guo B#; Jia Q; Qin D; Liu SQ; Wang Z; Xiang T; Zhang J; Tan Y; Huang J; Chen J; Wang F; Xiao M; Gao J; Yang X; Zeng H; Wang X; Hu C; Alexander PB; Symonds ALJ; Yu J; Wan Y; Li QJ; Ye L* Zhu B, 2018 Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer, Jia Q#; Wu W#; Wang Y; Alexander PB; Sun C; Gong Z; Cheng JN; Sun H; Guan Y; Xia X; Yang L; Yi X; Wan YY; Wang H; He J; Futreal PA; Li QJ, Zhu B, 2018 C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis, Liu J(#); Tan Y(#); Zhang J(#); Zou L; Deng G; Xu X; Wang F; Ma Z; Zhang J; Zhao T; Liu Y; Li Y; Zhu B(); Guo B(*), 2015

Areas of Focus

Tumor Immunology

Publications

Tumor-associated myeloid cells in cancer immunotherapy, Cheng X, Wang H, Wang Z, Zhu B*, Long H*, 2023
CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy, Xinxin Wang#, Haoran Zha#, Wei Wu, Ting Yuan, Shuanglong Xie, Zheng Jin, Haixia Long, Fei Yang, Zhongyu Wang, Anmei Zhang, Jianbao Gao, Ying Jiang, Lujing Wang, Chunyan Hu, Yisong Y. Wan, Qi-Jing Li, Alistair L.J. Symonds, Qingzhu Jia*, Bo Zhu*, 2023
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy, Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B, 2022
High-throughput single-сell sequencing in cancer research, Jia Q, Chu H, Jin Z, Long H*, Zhu B*, 2022
Modulating tumor physical microenvironment for fueling CAR-T cell therapy, Luo Z, Yao X, Li M, Fang D, Fei Y, Cheng Z, Xu Y*, Zhu B*, 2022
Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing During Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer, Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, Wu D, Li X, Sun J*, He L, Robinson B, Zhu B*, 2020
Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC, Wang Z, Jia Q, Tang X, Yan L, Zhu B*, 2020
The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection, Chen X#, Cao G#, Wu J#, Wang X#, Pan Z, Gao J, Tian Q, Xu L, Li Z, Hao Y, Huang Q, Wang P, Xiao M, Xie L, Tang S, Liu Z, Hu L, Tang J, He R, Wang L, Zhou X, Wu Y, Chen M, Sun B, Zhu B*, Huang J*, Ye L*, 2020
Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients with Lung Adenocarcinoma, Gong Z#; Jia Q#; Chen J; Diao X; Gao J; Wang X; Zhu B*, 2019
Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation, Zhou J#, Huang S#, Wang Z#, Huang J, Xu L, Tang X, Wan YY, Li QJ, Symonds ALJ, Long H*, Zhu B*, 2019
Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells, Zhao L#; He R#; Long H#; Guo B#; Jia Q; Qin D; Liu SQ; Wang Z; Xiang T; Zhang J; Tan Y; Huang J; Chen J; Wang F; Xiao M; Gao J; Yang X; Zeng H; Wang X; Hu C; Alexander PB; Symonds ALJ; Yu J; Wan Y; Li QJ*; Ye L* Zhu B*, 2018
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer, Jia Q#; Wu W#; Wang Y; Alexander PB; Sun C; Gong Z; Cheng JN; Sun H; Guan Y; Xia X; Yang L; Yi X; Wan YY; Wang H; He J; Futreal PA; Li QJ*, Zhu B*, 2018
C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis, Liu J(#); Tan Y(#); Zhang J(#); Zou L; Deng G; Xu X; Wang F; Ma Z; Zhang J; Zhao T; Liu Y; Li Y; Zhu B(*); Guo B(*), 2015

Tumor Immunology Cancer Therapy Immune Cells Molecular Mechanism Treatment Research

Kong Wei - Peking University

Xunde Xian - Peking University

Xiaowei Zhang - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us